Adage Capital Discloses 5.45% Stake in Tango Therapeutics (5.9M)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 5,905,349 shares of Tango Therapeutics common stock, equal to 5.45% of the company’s outstanding shares based on an 108,394,190 share count used in the filing. The reported position shows shared voting and dispositive power of 5,905,349 shares and no sole voting or dispositive power.
The filing is submitted on Schedule 13G and states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Positive
- Material disclosed stake: Reporting Persons beneficially own 5,905,349 shares (5.45%), exceeding the 5% reporting threshold.
- Passive classification: The filing is on Schedule 13G and states the securities are held in the ordinary course of business and not to change control.
Negative
- No sole voting or dispositive power is reported, indicating the Reporting Persons do not control voting decisions for the shares.
Insights
TL;DR: Adage holds a material passive stake (5.45%) in Tango, signaling meaningful investor interest without control intent.
Adage’s disclosed 5,905,349-share position represents a material ownership level above the 5% reporting threshold and is calculated against 108,394,190 shares outstanding as referenced in the filing. The filing under Schedule 13G and the explicit certification that the securities are held in the ordinary course indicate a passive investment stance rather than an active campaign for control. For market participants, this confirms institutional attention while maintaining the company’s existing governance structure.
TL;DR: The reporters disclose only shared voting/dispositive power and assert passive intent, so governance control is not indicated.
The statement shows no sole voting or dispositive power and only shared authority over the 5.45% stake. The Schedule 13G classification and the certification language reduce the likelihood that this holding will be treated as an attempt to influence board composition or corporate control. That said, a >5% passive stake can still prompt issuer engagement; the filing itself contains no indication of activist intent or proposed governance actions.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who filed the Schedule 13G for Tango Therapeutics (TNGX)?
What percent of Tango Therapeutics does the reported stake represent?
Is the position reported as passive or activist?
AI-generated analysis. How Rhea-AI works. Not financial advice.